| Gene symbol | CLU | Synonyms | AAG4, APO-J, APOJ, CLI, CLU1, CLU2, KUB1, NA1/NA2, SGP-2, SGP2, SP-40, TRPM-2, TRPM2 | Type of gene | protein-coding |
| Chromosome | 8 | Map location | 8p21.1 | dbXrefs | |
| Description | clusterin | ||||
| GTO ID | GTC1346 |
| Trial ID | NCT01083615 |
| Disease | Prostate Cancer |
| Altered gene | CLU |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | OGX-011|custirsen sodium|TV-1011 |
| Co-treatment | docetaxel|cabazitaxel|prednisone |
| Phase | Phase3 |
| Recruitment status | Terminated |
| Title | A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer |
| Year | 2010 |
| Country | Canada|France|Spain|United Kingdom|United States |
| Company sponsor | Achieve Life Sciences |
| Other ID(s) | OGX-011-10 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||